Tourmaline Bio Inc
NASDAQ:TRML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Poonawalla Fincorp Ltd
NSE:POONAWALLA
|
IN |
|
Sendas Distribuidora SA
BOVESPA:ASAI3
|
BR |
Tourmaline Bio Inc
Other Current Assets
Tourmaline Bio Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tourmaline Bio Inc
NASDAQ:TRML
|
Other Current Assets
$11m
|
CAGR 3-Years
64%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$1.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
Tourmaline Bio Inc
Glance View
Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.
See Also
What is Tourmaline Bio Inc's Other Current Assets?
Other Current Assets
11m
USD
Based on the financial report for Dec 31, 2024, Tourmaline Bio Inc's Other Current Assets amounts to 11m USD.
What is Tourmaline Bio Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
44%
Over the last year, the Other Current Assets growth was 86%. The average annual Other Current Assets growth rates for Tourmaline Bio Inc have been 64% over the past three years , 44% over the past five years .
